Additional file 1 of Safety and efficacy of cell therapies in pediatric heart disease: a systematic review and meta-analysis
Creators: name: Martinez, John
name: Zoretic, Sarah
name: Moreira, Axel
name: Moreira, Alvaro
Publisher: name: figshare
Year: 2020
Subjects: subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Pharmacology
subject: Biotechnology
subject: Developmental Biology
subject: Cancer
subject: Hematology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences
subject: FOS: Health sciences

description: Additional file 1 Supplemental 1. PROSPERO registration Supplemental 2. SYRCLE criteria for animal intervention studies. Supplemental 3. Database search terms. Supplemental 4. List of included studies. Supplemental 5. PRISMA Checklist. Supplemental 6. Effect size of regenerative cell on animal ejection fraction. Forest plots demonstrating MD and 95% CI for A) Left ventricular ejection fraction; cell-based n=172; control=177; p &lt;0.0001. B) Right ventricular ejection fraction; cell-based n=84; control n=84; p=0.02. C) Disease model; cell-based n= 256; control n=261; RVHF, p=0.01; DCM, p&lt;0.0001. Supplemental 7. Subgroup analysis of regenerative cell effect size on animal ejection fraction. Forest plots demonstrating MD and 95% CI for A) Route of delivery, p&lt;0.00001 for intramyocardial injection. B) Dose, p&lt;0.00001 for 1-10 M. C) Tissue Source, p&lt;0.0001 for cardiac; p=0.0003 for bone marrow. D) Timing of delivery, p&lt;0.0001 for 1 week–1 month. E) autologous vs. non-autologous sources, p&lt;0.0001 (non-autologous). Cell-based n=256; Control n=261. Supplemental 8. Subgroup analysis of regenerative cell effect size on animal fractional shortening. Forest plots demonstrating MD and 95% CI for A) Route of delivery, p=0.001 for intramyocardial. B) Dose, p=0.001 for &gt;10 M cells/kg. C) Tissue Source, p=0 .001 for umbilical cord blood. D) Timing of delivery, p=0.001 for &gt;1 month. E) Disease model, p=0.001 for dilated cardiomyopathy. Cell-based n=175; Control n=171. Supplemental 9. Effect size of regenerative cell on additional measures of animal cardiac function. Forest plots demonstrating MD and 95% CI for A) Fractional area change, p=0.05; cell-based n= 33; control n=30. B) End diastolic volume, p=0.48; cell-based n=67; control n=61. C) End systolic volume, p=0.60; cell-based n=72; control n=66. D) Tricuspid annular plane systolic excursion, p=0.55; cell-based n=33; control n=58. Supplemental 10. Effect size of regenerative cell on additional measures of human cardiac function. Forest plots demonstrating MD and 95% CI for A) Fractional area change, p-0.19; cell-based n=62; control n=62. B) End diastolic volume, p=0.52; cell-based n=110; control n=110. C) End systolic volume, p=0.96; cell-based n=110; control n=110. Supplemental 11. SYRCLE risk of bias for animal studies. Supplemental 12. ROBINS-I risk of bias for human studies. Supplemental 13. Funnel plot diagram for animal ejection fraction. Supplemental 14. Funnel plot diagram for animal fractional shortening. Supplemental Table 1. Animal study intervention characteristics. Supplemental Table 2. Adverse events by systems. Supplemental Table 3. Animal adverse events. Supplemental Table 4. Human study intervention characteristics. Supplemental Table 5. Human adverse events. Supplemental Table 6. Clinical trials, ongoing.